Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways

Osteoporosis, which typically affects postmenopausal women, is an osteolytic disease due to over-activation of osteoclasts. However, current drugs targeting osteoclast inhibition face various side effects, making natural compounds with great interest as alternative treatment options. Cycloastragenol...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gang, Ma, Chao, Chen, Kai, Wang, Ziyi, Qiu, Heng, Chen, Delong, He, Jianbo, Zhang, Cheng, Guo, Ding, Lai, Boyong, Zhang, Shuangxiao, Huang, Linfeng, Yang, Fan, Yuan, Jinbo, Chen, Leilei, He, Wei, Xu, Jiake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812338/
https://www.ncbi.nlm.nih.gov/pubmed/35126144
http://dx.doi.org/10.3389/fphar.2021.810322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812338/
https://www.ncbi.nlm.nih.gov/pubmed/35126144
http://dx.doi.org/10.3389/fphar.2021.810322

Ejemplares similares